Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference

M-protein kinetics in multiple myeloma treated with melphalan, ifosfamide, prednisolone, nitrosourea and vincristine in combination.

Ishii, Hirofumi

October 1988

Patients with multiple myeloma were treated chemotherapeutically with a combination of melphalan, if...

Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes

Rutella, S
Locatelli, F

January 2012

Multiple myeloma (MM) is a plasma cell malignancy associated with high levels of monoclonal (M) prot...

The role of monoclonal antibodies in smoldering and newly diagnosed transplant-eligible multiple myeloma

Zamagni E.
Tacchetti P.
Deias P.
Patriarca F.

January 2020

The recent introduction of monoclonal antibodies (MoAbs), with several cellular targets, such as CD-...

Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference

McCudden, C.
Axel, A.E.
Slaets, D.
Dejoie, T.
Clemens, P.L.
Frans, S.
Bald, J.
Plesner, T.
Jacobs, J.F.M.
Donk, N.W. van de
Moreau, P.
Schecter, J.M.
Ahmadi, T.
Sasser, A.K.

January 2016

BACKGROUND: Monoclonal antibodies are promising anti-myeloma treatments. As immunoglobulins, monoclo...

Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)

Donk, N.W. van de
Otten, H.G.
Haddad, O. El
Axel, A.
Sasser, A.K.
Croockewit, A.J.
Jacobs, J.F.M.

January 2016

Contains fulltext : 172840.pdf (Publisher’s version ) (Open Access)Daratumumab is ...

Antibody Therapies for Multiple Myeloma

Kanellias, Nikolaos
Gavriatopoulou, Maria
Terpos, Evangelos

July 2021

Multiple Myeloma (MM) is characterized by the abberant proliferation and expansion of plasma cells i...

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma

Donk, Niels W. C. J. van de
Moreau, Philippe
Plesner, Torben
Palumbo, Antonio
Gay, Francesca
Laubach, Jacob P.
Malavasi, Fabio
Avet-Loiseau, Hervé
Mateos, Maria Victoria
Sonneveld, Pieter
Lokhorst, Henk M.
Richardson, Paul G.

August 2018

Immunotherapeutic strategies are emerging as promising therapeutic approaches in multiple myeloma (M...

New developments in the treatment of multiple myeloma – clinical utility of daratumumab

McEllistrim C
Krawczyk J
O'Dwyer ME

April 2017

Cian McEllistrim,1 Janusz Krawczyk,1 Michael E O’Dwyer1,2 1Department of Hematology, Universit...

Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M‑Protein in the Presence of Therapeutic Monoclonal Antibodies

Marina Zajec (4857892)
Joannes F. M. Jacobs (1548406)
Patricia J. T. A. Groenen (4857883)
Corrie M. de Kat Angelino (4857886)
Christoph Stingl (242928)
Theo M. Luider (242944)
Yolanda B. De Rijke (4857889)
Martijn M. VanDuijn (557921)

February 2018

M-protein diagnostics can be compromised for patients receiving therapeutic monoclonal antibodies as...

Monoclonal antibodies in the treatment of multiple myeloma

Richardson, Paul G.
Lonial, Sagar
Jakubowiak, Andrzej J.
Harousseau, Jean‐luc
Anderson, Kenneth C.

September 2011

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/86883/1/j.1365-2141.2011.08790.x.pd

Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow

Langerhorst, P.
Noori, S.
Zajec, M.
Rijke, Y.B. de
Gloerich, J.
Gool, A.J. van
Caillon, H.
Joosten, I.
Luider, T.M.
Corre, J.
VanDuijn, M.M.
Dejoie, T.
Jacobs, J.F.M.

January 2021

Contains fulltext : 244656.pdf (Publisher’s version ) (Open Access

Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders : an International Myeloma Working Group Mass Spectrometry Committee Report

Murray, David L.
Puig, Noemi
Kristinsson, Sigurður Yngvi
Usmani, Saad Z.
Dispenzieri, Angela
Bianchi, Giada
Kumar, Shaji
Chng, Wee Joo
Hajek, Roman
Paiva, Bruno
Waage, Anders
Rajkumar, S. Vincent
Durie, Brian

February 2021

Daratumumab for the treatment of multiple myeloma

Touzeau, Cyrille
Moreau, Philippe

January 2017

International audienceProteasome inhibitors and immunomodulatory drugs have contributed to the drama...

New developments in the treatment of multiple myeloma &ndash; &lt;br /&gt;clinical utility of daratumumab

McEllistrim, Cian
Krawczyk, Janusz
O\u27Dwyer, Michael

September 2018

Multiple myeloma is a clonal disorder of plasma cells that is currently considered incurable. CD38 i...

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

June 2017

none20siMonoclonal antibodies (mAbs) are a recent addition to multiple myeloma (MM) therapies and a ...

M-protein kinetics in multiple myeloma treated with melphalan, ifosfamide, prednisolone, nitrosourea and vincristine in combination.

Ishii, Hirofumi

October 1988

Patients with multiple myeloma were treated chemotherapeutically with a combination of melphalan, if...

Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes

Rutella, S
Locatelli, F

January 2012

Multiple myeloma (MM) is a plasma cell malignancy associated with high levels of monoclonal (M) prot...

The role of monoclonal antibodies in smoldering and newly diagnosed transplant-eligible multiple myeloma

Zamagni E.
Tacchetti P.
Deias P.
Patriarca F.

January 2020

The recent introduction of monoclonal antibodies (MoAbs), with several cellular targets, such as CD-...

Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference

McCudden, C.
Axel, A.E.
Slaets, D.
Dejoie, T.
Clemens, P.L.
Frans, S.
Bald, J.
Plesner, T.
Jacobs, J.F.M.
Donk, N.W. van de
Moreau, P.
Schecter, J.M.
Ahmadi, T.
Sasser, A.K.

January 2016

BACKGROUND: Monoclonal antibodies are promising anti-myeloma treatments. As immunoglobulins, monoclo...

Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)

Donk, N.W. van de
Otten, H.G.
Haddad, O. El
Axel, A.
Sasser, A.K.
Croockewit, A.J.
Jacobs, J.F.M.

January 2016

Contains fulltext : 172840.pdf (Publisher’s version ) (Open Access)Daratumumab is ...

Antibody Therapies for Multiple Myeloma

Kanellias, Nikolaos
Gavriatopoulou, Maria
Terpos, Evangelos

July 2021

Multiple Myeloma (MM) is characterized by the abberant proliferation and expansion of plasma cells i...

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma

Donk, Niels W. C. J. van de
Moreau, Philippe
Plesner, Torben
Palumbo, Antonio
Gay, Francesca
Laubach, Jacob P.
Malavasi, Fabio
Avet-Loiseau, Hervé
Mateos, Maria Victoria
Sonneveld, Pieter
Lokhorst, Henk M.
Richardson, Paul G.

August 2018

Immunotherapeutic strategies are emerging as promising therapeutic approaches in multiple myeloma (M...

New developments in the treatment of multiple myeloma – clinical utility of daratumumab

McEllistrim C
Krawczyk J
O'Dwyer ME

April 2017

Cian McEllistrim,1 Janusz Krawczyk,1 Michael E O’Dwyer1,2 1Department of Hematology, Universit...

Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M‑Protein in the Presence of Therapeutic Monoclonal Antibodies

Marina Zajec (4857892)
Joannes F. M. Jacobs (1548406)
Patricia J. T. A. Groenen (4857883)
Corrie M. de Kat Angelino (4857886)
Christoph Stingl (242928)
Theo M. Luider (242944)
Yolanda B. De Rijke (4857889)
Martijn M. VanDuijn (557921)

February 2018

M-protein diagnostics can be compromised for patients receiving therapeutic monoclonal antibodies as...

Monoclonal antibodies in the treatment of multiple myeloma

Richardson, Paul G.
Lonial, Sagar
Jakubowiak, Andrzej J.
Harousseau, Jean‐luc
Anderson, Kenneth C.

September 2011

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/86883/1/j.1365-2141.2011.08790.x.pd

Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow

Langerhorst, P.
Noori, S.
Zajec, M.
Rijke, Y.B. de
Gloerich, J.
Gool, A.J. van
Caillon, H.
Joosten, I.
Luider, T.M.
Corre, J.
VanDuijn, M.M.
Dejoie, T.
Jacobs, J.F.M.

January 2021

Contains fulltext : 244656.pdf (Publisher’s version ) (Open Access

Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders : an International Myeloma Working Group Mass Spectrometry Committee Report

Murray, David L.
Puig, Noemi
Kristinsson, Sigurður Yngvi
Usmani, Saad Z.
Dispenzieri, Angela
Bianchi, Giada
Kumar, Shaji
Chng, Wee Joo
Hajek, Roman
Paiva, Bruno
Waage, Anders
Rajkumar, S. Vincent
Durie, Brian

February 2021

Daratumumab for the treatment of multiple myeloma

Touzeau, Cyrille
Moreau, Philippe

January 2017

International audienceProteasome inhibitors and immunomodulatory drugs have contributed to the drama...

New developments in the treatment of multiple myeloma &ndash; &lt;br /&gt;clinical utility of daratumumab

McEllistrim, Cian
Krawczyk, Janusz
O\u27Dwyer, Michael

September 2018

Multiple myeloma is a clonal disorder of plasma cells that is currently considered incurable. CD38 i...

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

June 2017

none20siMonoclonal antibodies (mAbs) are a recent addition to multiple myeloma (MM) therapies and a ...

M-protein kinetics in multiple myeloma treated with melphalan, ifosfamide, prednisolone, nitrosourea and vincristine in combination.

Ishii, Hirofumi

October 1988

Patients with multiple myeloma were treated chemotherapeutically with a combination of melphalan, if...

Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes

Rutella, S
Locatelli, F

January 2012

Multiple myeloma (MM) is a plasma cell malignancy associated with high levels of monoclonal (M) prot...

The role of monoclonal antibodies in smoldering and newly diagnosed transplant-eligible multiple myeloma

Zamagni E.
Tacchetti P.
Deias P.
Patriarca F.

January 2020

The recent introduction of monoclonal antibodies (MoAbs), with several cellular targets, such as CD-...

Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference

Abstract

Extracted data

Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference

Abstract

Extracted data

Related items

Related items